

Hong Kong Exchanges and Clearing Limited and The Stock Exchange of Hong Kong Limited take no responsibility for the contents of this announcement, make no representation as to its accuracy or completeness and expressly disclaim any liability whatsoever for any loss howsoever arising from or in reliance upon the whole or any part of the contents of this announcement.



Zylox-Tonbridge Medical Technology Co., Ltd.

歸創通橋醫療科技股份有限公司

(A joint stock company incorporated in the People's Republic of China with limited liability)

(Stock Code: 2190)

PROPOSED AMENDMENTS TO THE ARTICLES OF ASSOCIATION

This announcement is made by Zylox-Tonbridge Medical Technology Co., Ltd. (the “**Company**”) pursuant to Rule 13.51(1) of the Rules Governing the Listing of Securities (the “**Listing Rules**”) on The Stock Exchange of Hong Kong Limited (the “**Stock Exchange**”).

On 18 April 2023, in order to, among other things, (i) reflect and align with the new requirements under the amendments on the Listing Rules with effect from 1 January 2022; and (ii) remove the class meetings and related requirements, the board (the “**Board**”) of directors (the “**Director(s)**”) proposed to put forward to the shareholders of the Company (the “**Shareholder(s)**”) for approval at the forthcoming annual general meeting of the Company (the “**2022 AGM**”) a special resolution to amend the existing articles of association of the Company (the “**Articles of Association**”).

The proposed amendments to the existing Articles of Association (the “**Proposed Amendments**”) are mainly related to shareholder protection standards set out in Appendix 3 to the Listing Rules and consequential amendments, as well as to reflect the “Trial Administrative Measures of Overseas Securities Offering and Listing by Domestic Companies” and relevant provisions announced by the China Securities Regulatory Commission on 17 February 2023 and other housekeeping amendments. Full version of the Proposed Amendments will be set out in the appendix to the circular to be dispatched to the Shareholders. The Board is of the view that the Proposed Amendments are in the interests of the Company and the Shareholders as a whole. The Proposed Amendments are subject to the approval of the Shareholders by way of special resolution at the 2022 AGM and, if approved, will become effective upon such approval. Special resolutions will also be proposed at the 2022 AGM for the Shareholders to consider and approve the (i) change of scope of business of the Company; and (ii) change of registered office of the Company. Prior to the passing of the relevant special resolutions at the 2022 AGM, the prevailing Articles of Association shall remain valid.

After the Proposed Amendments come into effect, the full text of the revised Articles of Association will be published on the Company's website (<http://www.zyloxtb.com>) and the Stock Exchange's website (www.hkexnews.hk).

A circular containing, among other things, full version of the Proposed Amendments together with the notice of the 2022 AGM will be dispatched to the Shareholders in due course.

By order of the Board
Zylox-Tonbridge Medical Technology Co., Ltd.
Dr. Jonathon Zhong Zhao
Chairman and Executive Director

Hong Kong, 18 April 2023

As of the date of this announcement, the Board comprises Dr. Jonathon Zhong Zhao, Mr. Yang Xie and Dr. Zheng Li as executive Directors, Mr. Stephen Hui Wang, Dr. Steven Dasong Wang and Mr. Dongfang Li as non-executive Directors, and Dr. Jian Ji, Mr. Hongze Liang and Ms. Yun Qiu as independent non-executive Directors.